一种放射性碘难治性分化型甲状腺癌的生物标记物及应用
Metabolomics analysis identified acetoacetic acid, which enhances the radioactive iodine uptake capacity of thyroid cancer cells, solving the diagnostic and treatment challenges of RAIR-DTC and providing new treatment options, including drugs and ketogenic diets, which significantly inhibit tumor growth and improve prognosis.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- ZHEJIANG CANCER HOSPITAL
- Filing Date
- 2023-12-08
- Publication Date
- 2026-07-17
AI Technical Summary
Current technologies are insufficient for the effective diagnosis and treatment of radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC), and treatment options are limited, resulting in poor patient prognosis.
LC-MS analysis was used to compare RAIR and NonRAIR clinical tissue samples to identify metabolites associated with RAIR-DTC, particularly acetoacetic acid, which enhances the radioactive iodine uptake capacity of thyroid cancer cells through the ketone body metabolic pathway. Furthermore, the radioactive iodine uptake capacity of RAIR-DTC was reversed by acetoacetic acid supplementation, including through medication or a ketogenic diet.
Supplementation with acetoacetic acid significantly enhances the uptake of radioactive iodine by thyroid cancer cells, allowing 131I to be used again for treatment, inhibiting tumor growth, reducing Ki67 expression, increasing NIS expression, and providing a new approach to treating RAIR-DTC.
Smart Images
Figure CN118259005B_ABST